EVOLUTION AT MERCK - INVENTING FOR LIFE

PNEUMOCCOCAL MARKET EXPECTED TO REMAIN LARGE WITH SIGNIFICANT ADDITIONAL OPPORTUNITY . • PEDIATRICS ADULTS Represent two-thirds of market Even with vaccine progress, still close to 500,000 deaths annually in children <5 years old around the world Children <5, % IPD Coverage Residual Disease Post-PCV13 • Significant remaining opportunity driven by aging population, limited National Immunization Programs and low vaccination rates (~400,000 hospitalization per year in the U.S.) Adults ≥65, % IPD Coverage Residual Disease Post-PCV13 100 Percent of residual disease 75 50 25 0 PCV13 V114 Other Ped PCVs ■PCV13 ■22F/33F ■ Additional 100 Percent of residual disease 75 75 50 50 25 0 PCV13 V114 ■PCV13 ■22F/33F ■ Additional PPV23 V116 MERCK INVENTING FOR LIFE Mike Nally I 65

View entire presentation